Buccal Drug Delivery System Market Expected To Grow At 10.7% CAGR Through 2030: What Businesses Need To Know
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Buccal Drug Delivery System Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The market for buccal drug delivery systems has seen significant growth in recent years. This market is expected to increase from $3.89 billion in 2025 to $4.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. The historical growth can be linked to factors such as a rising preference for alternative drug administration methods, an expansion in treatments for chronic pain and angina, progress in mucoadhesive formulations, a growing demand for medications with quicker onset, and the broadening of oral pharmaceutical manufacturing.
The market for buccal drug delivery systems is anticipated to expand quickly over the coming years. Its valuation is projected to reach $6.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This expansion during the projection period stems from factors such as augmented investments in transmucosal drug investigations, a heightened need for smoking cessation treatments, the proliferation of personalized drug delivery systems, a stronger emphasis on formulations that promote compliance, and the accelerated creation of innovative buccal medications. Key trends anticipated during the forecast period encompass a wider acceptance of buccal and sublingual dosage methods, an escalating requirement for swift drug absorption mechanisms, a greater concentration on drug delivery systems that are convenient for patients, the evolution of controlled-release buccal formulations, and an intensified focus on non-invasive therapeutic options.
Get A Free Sample Report With In-Depth Market Insights:
Buccal Drug Delivery System Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing occurrence of long-term illnesses is anticipated to fuel the expansion of the buccal drug delivery systems market in the future. Chronic conditions are defined as health problems lasting a year or more, including examples like cancer, heart disease, stroke, diabetes, and arthritis. These common chronic ailments, which require ongoing nutritional and medical support, are manageable but currently incurable. For many individuals living with chronic diseases like diabetes and cancer, buccal drug delivery systems offer suitable and efficient methods for administering mucosal and transmucosal medications. As an illustration, in June 2024, data from the National Health Service, a UK-based government body, indicated that in 2023, 3,615,330 people registered with a general practitioner (GP) were identified with non-diabetic hyperglycemia or pre-diabetes (a state of elevated blood sugar not yet meeting diabetes criteria). This represented an 18% rise from 3,065,825 instances recorded in 2022. Consequently, the growing incidence of chronic conditions is a key factor boosting the expansion of the buccal drug delivery systems market.
Buccal Drug Delivery System Market Segments: Where Is Growth Concentrated?
The buccal drug delivery system market covered in this report is segmented –
1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users
Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels
Buccal Drug Delivery System Market Innovation Trends Shaping Future Development
Leading companies active in the buccal drug delivery systems market are concentrating on launching products, such as melatonin oral spray, to increase their revenues. Melatonin oral spray is a form of melatonin supplementation provided in a spray format for oral application. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced melatonin oral spray. This spray assists the body’s inherent melatonin production, consequently improving sleep quality in a straightforward and efficient manner. The medication offers a rapid remedy for individuals struggling with initiating sleep, maintaining sleep, or adjusting to various sleep patterns. Its swift and uncomplicated oral absorption facilitates a quicker initiation of sleep and enhanced sleep quality.
Buccal Drug Delivery System Market Company Landscape And Competitive Strategy
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc
View The Full Buccal Drug Delivery System Market Report:
Buccal Drug Delivery System Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
